FDA– tag –
-
Beam Therapeutics Receives FDA IND Clearance for Liver-Targeted LNP Formulation BEAM-304 for Phenylketonuria (PKU) Treatment
Beam Therapeutics USA Overview Beam Therapeutics announced FDA IND clearance for BEAM-304, a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents, for the treatment of Phenylketonuria (PKU). Designed to correct m... -
Top 10 Emerging Healthcare Technologies in 2026: CRISPR Gene Editing Established as Therapeutic Category, Regenerative Medicine Nearing Clinical Application
Slate USA Overview An article on 10 emerging healthcare technologies to watch in 2026 highlights that CRISPR gene editing is moving beyond the lab to become a bona fide therapeutic category. Additionally, regenerative medicine and stem c... -
Prime Medicine’s Autologous Prime Editing Hematopoietic Stem Cell Therapy PM359 for p47phox-Deficient Chronic Granulomatous Disease Receives FDA RMAT Designation
BiopharmaWatch (Prime Medicine Press Release) USA Overview Prime Medicine announced its investigational autologous prime editing hematopoietic stem cell therapy, PM359, for the treatment of p47phox-deficient Chronic Granulomatous Disease... -
Beam Therapeutics Gains FDA IND Approval for In Vivo Base Editing Therapy BEAM-304 for PKU
CRISPR Medicine News USA Overview Beam Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for BEAM-304, an in vivo base editing therapy targeting phenylketonuria (PKU). This therapy utilizes adenine base editing d... -
Automated Cell Therapy Manufacturing Lands $1.1 Billion Investment, Poised to Transform Commercialization and Patient Access
Tracxn (Indian Pharma Post経由) India Overview The automated cell therapy manufacturing sector has secured approximately $1.1 billion across 34 funding rounds, reflecting strong investor confidence and paving the way for scalable commerc... -
Intellia Therapeutics’ In Vivo CRISPR Therapy Lonvo-z Achieves 87% Attack Rate Reduction in HAE Phase 3 Trial, Initiates Rolling BLA Filing with FDA
Intellectia.AI USA Overview Intellia Therapeutics' in vivo CRISPR therapy, lonvo-z, demonstrated an 87% reduction in hereditary angioedema (HAE) attack frequency in its Phase 3 HAELO trial. Following these breakthrough results, the compa... -
CRISPR Gene Editing Advances in 2026: Accumulation of Clinical Data and Evolving Regulatory Framework for Rare Diseases, Cancer, and Autoimmune Disorders
Industry report / Analysis USA Overview The CRISPR gene editing landscape in 2026 shows significant progress across rare diseases, hematologic and solid cancers, and autoimmune disorders. Clinical programs are generating crucial data, wh... -
Beam Therapeutics Receives U.S. FDA IND Clearance for BEAM-304, a Base Editing Therapy for Phenylketonuria (PKU)
Beam Therapeutics USA Overview Beam Therapeutics announced U.S. FDA Investigational New Drug (IND) clearance for BEAM-304, its investigational base editing therapy for Phenylketonuria (PKU). This milestone paves the way for human clinica... -
FDA Approves First AI-Designed Drug Molecule for Phase 3 Clinical Trial in 2026, Accelerating R&D with New AI Drug Discovery Regulatory Guidance
BioNixus USA Overview In March 2026, the US FDA approved the first AI-designed drug molecule for Phase 3 clinical trials, solidifying AI drug discovery as a foundational technology in pharmaceutical R&D. Following this, on May 15th, ... -
Regulatory Complexity Challenges Cell-Cultivated Meat in the US, Highlighting Issues Between Federal Approval and State Legislation
PetfoodIndustry USA Overview The regulatory landscape for cell-cultivated meat products in the United States is becoming increasingly complex, posing challenges for manufacturers due to a mix of federal and state regulations. Despite USD...
